PMID: 15365306Sep 15, 2004Paper

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence

Alcoholism, Clinical and Experimental Research
Bankole A JohnsonElliot W Ehrich

Abstract

: Oral naltrexone is currently used as part of a treatment regimen for alcohol-dependent patients, but its clinical utility is hampered by poor patient adherence. A long-acting injectable naltrexone formulation (Vivitrex) was designed to facilitate patient adherence by providing an extended duration of therapeutic naltrexone over 1 month, thereby eliminating the need for daily dosing. : A multicenter, randomized, double-blind, placebo-controlled pilot study was conducted to evaluate the safety and tolerability of intramuscular repeat dose administration of this extended-release naltrexone formulation in DSM-IV alcohol-dependent patients. Thirty patients were randomized to treatment with injectable naltrexone (400 mg; n = 25) or a matching placebo injection (n = 5) and were dosed once every 28 days over 4 months. Psychosocial treatment was offered to patients in both treatment groups. Outcome measures related to drinking activity and trough plasma concentrations of naltrexone and its primary metabolite, 6-beta-naltrexol, were evaluated. : Injectable naltrexone was generally safe and well tolerated. Reported adverse events were mild to moderate and resolved without intervention; only two patients discontinued due to adverse event...Continue Reading

References

Nov 1, 1992·Archives of General Psychiatry·J R VolpicelliC P O'Brien
Nov 1, 1992·Archives of General Psychiatry·S S O'MalleyB Rounsaville
Jan 1, 1996·Alcohol·C P O'BrienJ R Volpicelli
Aug 1, 1997·Archives of General Psychiatry·J R VolpicelliC P O'Brien
May 13, 1999·The New England Journal of Medicine·R M Swift
Mar 25, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H R KranzlerJ Van Kirk
Jun 27, 2000·Psychopharmacology·B A Johnson, N Ait-Daoud
Nov 30, 2000·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·J ChickB Ritson
Dec 14, 2001·The New England Journal of Medicine·J H KrystalUNKNOWN Veterans Affairs Naltrexone Cooperative Study 425 Group
Mar 30, 2002·Alcoholism, Clinical and Experimental Research·Katherine M ConigraveUNKNOWN WHO/ISBRA Study Group

❮ Previous
Next ❯

Citations

May 27, 2006·Journal of Psychiatric Practice·Aron N StarostaJoseph R Volpicelli
Dec 14, 2007·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Thomas F BaborJeremy Bray
Jul 9, 2013·Indian Journal of Psychological Medicine·Aditya HegdeSiddharth Sarkar
Apr 8, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Nowsheen GoonooDhanjay Jhurry
Oct 18, 2007·Expert Review of Neurotherapeutics·Paolo MannelliAshwin A Patkar
Aug 10, 2007·Expert Opinion on Investigational Drugs·Sandra D ComerGary K Hulse
Jun 22, 2010·Expert Opinion on Emerging Drugs·Michael Soyka, Susanne Rösner
Jun 10, 2011·Expert Opinion on Investigational Drugs·Thomas HillemacherHelge Frieling
Mar 18, 2008·Pharmacology, Biochemistry, and Behavior·Reginald L DeanDavid R Gastfriend
Feb 5, 2008·Alcoholism, Clinical and Experimental Research·Michael R LuceyCharles P O'Brien
Jan 29, 2011·Annals of the New York Academy of Sciences·David R Gastfriend
May 11, 2011·CNS Neuroscience & Therapeutics·Philipp P LobmaierHelge Waal
Oct 13, 2015·Psychiatry Research·Sarah G Helton, Falk W Lohoff
Jul 31, 2013·Alcoholism, Clinical and Experimental Research·Raye Z LittenHsiao-ye Yi
Dec 20, 2008·Journal of Biomedical Materials Research. Part a·W O FaridG K Hulse
Dec 3, 2009·Alcoholism, Clinical and Experimental Research·Katherine G HillStephen W Kiefer
Mar 30, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Julia M A SinclairDavid S Baldwin
Aug 25, 2005·Clinical Therapeutics·Lisa A Boothby, Paul L Doering
May 19, 2016·Journal of Addictive Diseases·Diane M HerbeckDesirée Crèvecoeur-MacPhail
Jul 18, 2016·Advanced Drug Delivery Reviews·Anjali JainWahid Khan
Sep 18, 2007·Journal of Clinical Psychopharmacology·Stephanie S O'MalleyHenry R Kranzler
Feb 27, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert Swift
Sep 14, 2007·European Addiction Research·Hendrik G RoozenWim van den Brink
Apr 22, 2008·The Cochrane Database of Systematic Reviews·P LobmaierA Bjørndal
Sep 6, 2012·British Journal of Clinical Pharmacology·Gary K Hulse
Apr 24, 2008·The Medical Journal of Australia·Nicholas LintzerisPaul S Haber

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Alcoholism, Clinical and Experimental Research
Henry R KranzlerDrugAbuse Sciences Naltrexone Depot Study Group
Alcoholism, Clinical and Experimental Research
Joi L DunbarKenneth C Lasseter
Fundamental & Clinical Pharmacology
Sophie Tambour, Etienne Quertemont
Psychiatric Services : a Journal of the American Psychiatric Association
Katherine M HarrisKelli Dimidjian
© 2021 Meta ULC. All rights reserved